The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model. by Amin, Rada et al.
The class-specific BCR tonic signal modulates
lymphomagenesis in a c-myc deregulation transgenic
model.
Rada Amin, Abdelghafour Marfak, Ce´line Pangault, Christelle Oblet, Aure´lie
Chanut, Karin Tarte, Yves Denizot, Michel Cogne´
To cite this version:
Rada Amin, Abdelghafour Marfak, Ce´line Pangault, Christelle Oblet, Aure´lie Chanut, et
al.. The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc dereg-
ulation transgenic model.. Oncotarget, Impact journals, 2014, 5 (19), pp.8995-9006.
<http://bit.ly/1J3UnsW>. <10.18632/oncotarget.2297>. <hal-01067143>
HAL Id: hal-01067143
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01067143
Submitted on 23 Sep 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2014
The class-specific BCR tonic signal modulates lymphomagenesis 
in a c-myc deregulation transgenic model
Rada Amin1,2,3, Abdelghafour Marfak1 , Céline Pangault3, Christelle Oblet1,2, Aurélie 
Chanut1,2, Karin Tarte3, Yves Denizot1,2 and Michel Cogné1,2
1 Centre National de la Recherche Scientifique, Limoges, France 
2 Université de Limoges, Limoges, France 
3 INSERM UMR U917, Rennes, France 
Correspondence to: Michel Cogné, email: cogne@unilim.fr
Keywords: BCR, c-myc, lymphoma, IgA, B cell
Received: June 09, 2014 Accepted: July 31, 2014 Published: July 31, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Deregulation of c-myc by translocation onto immunoglobulin (Ig) loci can 
promote B cell malignant proliferations with phenotypes as diverse as acute lymphoid 
leukemia, Burkitt lymphoma, diffuse large B cell lymphoma, myeloma... The B cell 
receptor (BCR) normally providing tonic signals for cell survival and mitogenic 
responses to antigens, can also contribute to lymphomagenesis upon sustained ligand 
binding or activating mutations. BCR signaling varies among cell compartments and 
BCR classes. For unknown reasons, some malignancies associate with expression 
of either IgM or class-switched Ig. We explored whether an IgA BCR, with strong 
tonic signaling, would affect lymphomagenesis in c-myc IgH 3’RR transgenic mice 
prone to lymphoproliferations. Breeding c-myc transgenics in a background where IgM 
expression was replaced with IgA delayed lymphomagenesis. By comparison to single 
c-myc transgenics, lymphomas from double mutant animals were more differentiated 
and less aggressive, with an altered transcriptional program. Larger tumor cells more 
often expressed CD43 and CD138, which culminated in a plasma cell phenotype in 
10% of cases. BCR class-specific signals thus appear to modulate lymphomagenesis 
and may partly explain the observed association of specific Ig classes with human B 
cell malignancies of differential phenotype, progression and prognosis.
INTRODUCTION
In normal cells, c-myc oncogene expression is 
restricted to the early G1 phase of the cell cycle with a role 
in proliferation, differentiation, metabolism and apoptosis 
[1] . Deregulation of the c-myc gene is a constant feature 
of human Burkitt lymphoma (BL), with translocations 
linking c-myc to any of the immunoglobulin heavy or 
light chain (IgH, Igκ or Igλ) locus and with a phenotype 
that may vary from immature RAG expressing B cell 
lymphoma or leukemia to mature B cell lymphoma [2]. 
Translocation onto the IgH locus is also frequent in human 
myeloma and mouse plasmacytoma cases, suggesting 
that c-myc may participate to cell transformation at all 
stages of B cell differentiation. The frequency at which 
myc-driven malignancies occur clearly depends upon 
the cell microenvironment and the local production of 
cytokines. For example, inflammation-induced mouse 
plasmacytomas only develop in mice proficient for IL6 [3] 
and necessitates that these mice are kept in a conventional 
rather than specific pathogen free animal facility [4].
Beside oncogenes and the role of signals from the 
microenvironment, the phenotype of B cell malignancies 
also often involves signaling through the adaptive or 
innate immune receptors. The B cell receptor (BCR) is 
mandatory for survival of normal B cells by providing 
a ligand-independent tonic signal. It is also the main 
receptor controlling B cell activation during immune 
responses [5]. Expression of Ig of the various classes 
additionally has a clear influence on normal B cell fate 
[6-9]. 
In some cases of human lymphomas involving 
Epstein-Barr virus transformation, BCR-dependent 
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activation or survival signals may be replaced by 
surrogate signals provided by the viral protein LMP2A 
[10]. Alternatively, in diffuse large B cell lymphomas 
(DLBCL), the activated B cell (ABC) phenotype features 
NF-κB activation due to somatic mutations at various 
levels of the BCR or TLR signaling cascades (Igα, 
Igβ, CARD11, Myd88...) and results in chronic BCR 
signaling in the absence of any BCR ligand [11, 12]. In 
other malignancies, ligand-dependent BCR signaling 
likely occurs. In follicular lymphoma, BCR molecules 
carrying high-mannose N-glycans may contribute to 
lymphomagenesis through their binding of C-type 
lectins in the tumor microenvironment [13]. In chronic 
lymphocytic leukemia (CLL), cell-autonomous signaling 
constitutively results from expression of self-binding 
BCRs [14]. Altogether, BCR signaling appears as strongly 
contributing to B cell transformation. As for untransformed 
B cells, the downstream effects of ligand-dependent 
or independent signals might be modulated according 
to the BCR class and to the stage at which oncogenic 
mutations immortalize a given cell. Interestingly, some 
B cell tumors overwhelmingly express IgM (as in CLL, 
follicular lymphoma, BL, lymphoplasmacytic lymphoma, 
ABC-type DLBCL, while others overwhelmingly express 
class-switched Ig (as in myeloma and GC-type DLBCL) 
[15]. It is thus questionable whether, similarly to their 
untransformed counterparts, malignant B cells could be 
drawn towards different phenotypes dependent about the 
Ig class produced. 
We designed experiments in order to compare 
experimental B cell tumors induced by a similar oncogenic 
event, but in the context of either class-switched or IgM 
expression. We recently described a model of transgenic 
mice developing BL-like lymphomas with a mature B 
cell phenotype upon expression of a c-myc transgene. 
This transgene includes the four transcriptional enhancers 
(hs3a, hs1,2, hs3b and hs4) from the IgH locus 3′ 
regulatory region (3’RR), and is thus expressed at all 
stages of B cell differentiation, but with a higher activity at 
those stages undergoing terminal B cell differentiation and 
class switch recombination [16-21] . Transgenic animal 
carrying this c-myc3’RR transgene have been shown 
to develop BL in 75% of cases and diffuse anaplastic 
lymphomas in the remaining 25% [22]. Proliferations 
occurred with a still higher (100%) penetrance and 
were more heterogeneous in animal carrying both the 
c-myc3’RR transgene and p53 haploinsufficiency [23, 24]. 
Tumors from c-myc-3’RR mice were CD43 negative and 
had a mature B cell phenotype (B220+/IgM+/IgD+). In the 
present study, we introduced the c-myc3’RR transgene into 
a background carrying a homozygous mutation of the IgH 
locus (α1KI mice) [6-8]. This α1KI mutation corresponds 
to replacement of the Sµ region with a knock-in Cα IgH 
gene and replaces IgM/IgD expression by the premature 
expression of IgA. This forced expression of an IgA “class-
switched” BCR has been shown to mediate constitutive 
pre-activation of B cells, even in the absence of any 
BCR ligation [6-8]. The present study was conducted by 
comparing single mutant (c-myc transgenics) with double 
mutant c-myc/α1KI animals. We thus monitored the 
occurrence of B cell malignancies upon the influence of 
both c-myc oncogene deregulation and class-switched-type 
constitutive BCR signaling and analyzed the phenotype of 
the observed malignancies.
RESULTS
Generation of double mutant α1KI c-myc3’RR 
mice
A colony of homozygous α1KI animals was 
generated, all bearing a single copy of the integrated c-myc 
cassette [22]. Single mutant α1KI homozygous mice were 
studied in parallel, as well as single c-myc transgenic 
animals.
B cell development and Ig secretion in young 
transgenic mice
We analyzed B cells in 6 weeks-old transgenic 
mice, before any manifestation of disease. Spleen and 
lymph nodes (LNs) from α1KI mice and α1KI c-myc3’RR 
mice were similar (not shown). Numbers of B cells did 
not differ between homozygous α1KI mice and the double 
transgenic α1KI c-myc3’RR, neither in spleen (6.7 ± 
1.7% N=5 for α1KI versus 8.9 ± 2.1% N=5, i.e. 1.4 ± 0.4 
103 cells/µl vs 1.3 ± 0.19 103 cells/µl), nor in LNs (5.1 ± 
0.8%, n=3 vs 5.3 ± 1.2%, n=3, i.e. 0.62 ± 0.09 103 cells/
µl vs 0.44 ± 0.14 103 cells/µl) (supplemental Fig 1A). By 
contrast, in vitro B cell proliferative responses to anti-
CD40 plus IL4 were evaluated and proved higher in α1KI 
c-myc transgenic mice than in α1KI single mutant animals 
(supplemental Fig 1B). 
Delayed lymphomas in α1KI c-myc3’RR mice vs 
c-myc3’RR single transgenics
Lymphoma development and mean lifespan were 
quoted for 61 double mutant α1KI c-myc3’RR transgenic 
mice, 34 single mutant α1KI homozygous mice and 22 
single mutant c-myc3’RR animals. The overall tumor 
incidence in double mutant animals was 48% before 34 
weeks of age. As expected by comparison to α1KI mice 
not susceptible to lymphoma, α1KI c-myc3’RR mice 
showed significantly increased mortality (Gehan Breslow 
Wilcoxon test, p <0.0001) that resulted from c-myc-driven 
tumor development, with the mean age of death at about 
39 weeks (Fig 1A). This was significantly below the 
mortality observed in c-myc3’RR single transgenic mice 
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(Gehan Breslow Wilcoxon test, p <0.001), among which 
80% had developed tumors before 34 weeks of age (with 
mean age of death at 27 weeks). 
At necropsy, the α1KI c-myc3’RR had enlarged 
spleens, LNs and eventually liver (Fig 1B). All mice with 
tumors showed leukemic peripheral blood involvement 
with large circulating nucleolated lymphoma cells (Fig 1C, 
up). Histological analysis of tumors showed a “starry-sky” 
pattern reminiscent of human BL (Fig 1C, down). 
Phenotype of B cell lymphomas in α1KI 
c-myc3’RR mice
FACS analyses of 29 tumors from α1KI c-myc3’RR 
transgenics revealed two kinds of tumors, either 
lymphocytic (type I) or plasmocytic (type II). 
Lymphocytic (type I) tumors were the most 
frequent. They histologically resembled those tumors 
seen in c-myc single transgenics but could be further split 
in two subgroups according to CD43 expression: type Ia, 
IgA+/CD19+/B220+/CD43- (Fig 2, left, 9 cases) and type 
Ib, IgA+/CD19+/B220+/CD43+ (Fig 2, middle, 17 cases). 
Plasmablastic (type II) tumors occurred less 
frequently (3 cases, i.e. roughly 10%). They strongly 
differed from those tumors reported in c-myc single 
transgenics and corresponded to malignant plasmablasts 
(with an IgA-/CD19-/B220-/CD43+/CD138+ phenotype) 
(Fig 2, right, 3 cases). 
By comparison to polyclonal B cells from pre-
malignant animals, all lymphoma cases featured large B 
cells, with mean cell size increasing from type Ia to type 
Ib and to type II tumors (Fig 3A and B).
Lymphomas that developed in α1KI c-myc3’RR 
Figure 1: Generation of α1KI c-myc3’RR transgenic mice. (A) Survival curves of c-myc3’RR and α1KI c-myc3’RR mice. Twenty 
two c-myc3’RR mice (*), 61 α1KI c-myc3’RR transgenic mice () and 34 α1KI () mice were followed over a period of 60 weeks. (B) 
Enlarged organs from α1KI c-myc3’RR mice at the tumor development stage compared with organs from a control (*) α1KI c-myc3’RR at 
the pre-tumorous stage (Left: 2 representative tumorous spleens; right: 1 representative tumorous LN) (C) Histological features of tumors 
in double transgenic mice: (Up) Typical circulating tumor cells with a basophilic cytoplasm (original magnifications, x20). (Down) Sections 
of formalin-fixed, paraffin-embedded LNs were stained with hematoxylin-eosin.
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mice were checked for monoclonality by southern blot 
analysis of IgH gene configuration on tumor DNA samples 
taken at two different organ locations in each mouse. 
DNA from spleens of healthy α1KI controls showed 
the germline IgH band, whereas all tumors displayed 
rearranged bands with a monoclonal pattern (supplemental 
Fig 2).
The 29 α1KIc-myc3’RR tumors analyzed all 
overexpressed c-myc at the mRNA level (Fig 3C). We 
checked several α1KI c-myc3’RR tumors of either tumor 
subtype for potential mutations within c-myc and found it 
un-mutated in all cases analyzed. 
Transcriptome analysis in α1KI c-myc3’RR 
lymphomas 
The rare type II plasmablastic tumors arising in 
double transgenics obviously differed phenotypically 
from those seen in single c-myc transgenics and were 
not further explored at the mRNA level. Regarding type 
I lymphomas which were predominant and histologically 
reminiscent of those from c-myc single transgenic mice, 
we wondered whether subtle changes would be found 
by more in-depth molecular analyses. To thoroughly 
Figure 2: Analysis of lymphomas in α1KI c-myc3’RR mice. Tumors from 29 mice were stained with different cell surface markers 
and felt into 3 tumor types, for each of which one representative case is shown: Ia: CD19+/B220+/human IgA+/CD43-/CD138- ; Ib: CD19+/
human IgA+/B220+/CD43+/CD138- and II: B220-/CD138+.
Oncotarget5www.impactjournals.com/oncotarget
compare double mutant vs single c-myc transgenic mice 
tumors, we thus analyzed gene expression profiles of 8 
IgA-expressing type I lymphomas (including 4 type Ia 
and 4 type Ib tumors) from double mutant mice compared 
to 8 IgM-expressing c-myc3’RR lymphomas (including 
4 “BL-like” and 4 anaplastic lymphomas). Analysis was 
performed to identify differentially expressed genes, either 
significantly up-regulated or down-regulated in tumors 
from both groups of mice (Table 1 and supplemental 
Table 1). As previously described, lymphomas from 
c-myc single transgenics (whether BL-like or anaplastic) 
had roughly homogeneous profiles (Supplemental Fig 3) 
[22]. By contrast, the 8 α1KI tumors expressing an IgA 
BCR featured a clearly different gene expression profile, 
with 97 genes found up-regulated while 116 were down-
regulated (both in type Ia and Ib tumors, whose profiles 
were roughly similar despite the differences regarding 
cell size and CD43 surface expression) (Table 1, 
Supplemental Fig. 3). Genes were classified according to 
their biological function (Table 1) and we used Ingenuity 
Pathway Analysis (IPA; Ingenuity Systems) to identify 
pathways that were enriched in the 2 lists reported in 
supplemental Table 2. The largest category of up-regulated 
genes involved ribosome biogenesis and protein synthesis 
(Table 1). These processes notably modulate cell growth 
and proliferation, and are frequently deregulated in 
cancer by influencing expression of oncogenes and tumor 
suppressors [28]. By itself, c-myc overexpression is known 
to stimulate ribosome assembly and result in increased cell 
size and protein synthesis [29].
Three genes negatively controlling cell proliferation 
were also strongly up-regulated in IgA-expressing tumors 
and may participate in delaying lymphomagenesis: the 
GADD34/ Ppp1r15a gene (up-regulated 12 fold) controls 
growth arrest during the unfolded protein response (UPR) 
[30]; Gas5 (overexpressed 12 fold) is transcribed into a 
noncoding RNA that induces growth arrest [31], while 
Btg1 (up-regulated 5 fold) is another inhibitor of cell 
proliferation [32]. By contrast, 4 down-regulated genes are 
tumor suppressors (Lxn, Rassf4, Dusp16, Ifitm2) [33-37].
Variations of another 3 genes could be connected 
with B cell activation: CD69 was overexpressed 4 fold 
in IgA tumors (similar to its overexpression polyclonal 
α1KI B cells) [6, 38] ); Trim12 (a repressor of lymphocyte 
activation) [39] was down-regulated 27 fold in IgA+ 
tumors, so as the gene for MARCH1, an E3 ubiquitin 
protein ligase targeting some membrane receptors for 
degradation and down-regulated by B cell activation [40]. 
Some other changes were related to membrane 
receptor expression or membrane trafficking, with notably 
a 3 fold increase in expression of the EHD2 ATP-ase, 
which stabilizes caveolae at the plasma membrane [41], 
and down-regulation of 15 other genes involved in related 
functions (Slc7a7, Slc39a4, Ggh, Sirpa, Rap1gap, H2afb3-
ps, Slc37a2, Ctsd, Arhgap9, Gng12, Eml2, Ctsh Gpr18). 
Expression of Fcγr4 and of the γ chain of FcγR1 was also 
down-regulated.
Some changes were related to signal transduction 
and may notably increase tyrosine kinase and wnt signals 
in IgA-expressing tumors, with 5 fold increased Lgr5 
(an activator of wnt signaling) [42] and a 3 fold down-
regulation of two wnt inhibitors, Trim59 (a repressor 
of c-myc-dependent wnt induction) [43] and the CD9 
tetraspanin which inhibits wnt/β-catenin signalization) 
[44]. Interestingly, two tyrosine kinase inhibitors are down 
regulated by 12 fold in IgA tumors: Lst1 a membrane 
adaptor recruiting phosphatases SHP1 and SHP2, and the 
DAP12 gene encoding tyrosine kinase binding protein 
Table 1: List of genes up-regulated and down-regulated in tumors of α1KI c-myc3’RR vs c-myc3’RR mice, 
according to their biological function.
Category of genes Up Down
Ribosome biogenesis and protein synthesis 24 9
Transcription factors and DNA-binding proteins 16 5
Highly expressed in immune system 9 20
Intracellular signal transduction modulators and effectors 10 28
metabolic enzyme-related proteins 2 16
Lipid metabolism 6 7
Cell cycle 2 4
Apoptose 4 0
Cell-adhesion-related proteins 2 6
Blood coagulation proteins 0 4
Mitochondrial-related protein 5 2
Others 17 15
TOTAL 97 116
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TyroBP [45, 46]. NFATc2, a transcription factor involved 
in B cell anergy and whose defect has been correlated with 
B cell hyper-responsiveness is down-regulated 5 fold [47]. 
We also noticed a 4-fold increased expression of Dusp6, 
an inhibitory MAP kinase phosphatase, down-regulation 
(10-fold) of Nafm1, an ITAM receptor that modulates BCR 
signaling [48] and of Hck , a src family kinase expressed 
in B cell progenitors [49]. 
Another major gene category included additional 
transcription factors, DNA-binding proteins and histones, 
with strong up-regulation of the Fos-B transcription factor 
gene (FBJ osteosarcoma oncogene B) (P= 9.95E-05). Fos 
family proteins form heterodimers with jun family proteins 
and constitute AP-1 transcriptions factors. These factors 
regulate the expression of multiple genes modulating cell 
proliferation, activation, differentiation and eventually cell 
death [50-53]. 
Interestingly, Ingenuity Pathway Analysis of down-
regulated genes pointed out that significantly enriched 
biologic functions were linked to cellular movement, 
immune cell trafficking and hematological system 
development and function (supplemental Table 2). 
Finally, some variations might be correlated 
with the control of the tumor niche and of anti-tumor 
immunity, such as ebi3, a subunit of IL27 normally 
over-expressed in centrocytes (and down 16 fold in IgA 
tumors) [54], CCL9 (down 10 fold in IgA tumors), a 
chemokine known to attract CCR1-expressing stromal 
cells and also expressed in macrophages and myeloid 
cells [55, 56], the nab2 transcription factor (known to 
stimulate TRAIL expression) down-regulated 6 times 
[57], the 10-fold overexpressed pvrl2 (an inhibitor of NK 
cytotoxicity) [58], the 3-fold overexpressed cortistatin (an 
immunomodulatory anti-inflammatory peptide produced 
by immune cells) [59], and the 2.8-fold overexpressed 
CCL25, a chemokine normally attracting lymphocytes to 
the small bowel [60].
DISCUSSION
Expression of the BCR is a major regulator of B 
cell fate, with signaling thresholds that vary between 
B1, follicular or marginal zone B cells. The tonic signal 
provided by BCR expression without any need for an 
extra-cellular ligand is mandatory for B cell survival and 
has also been reported as increased by class switching to 
the IgG or IgA class [6, 8, 61].
All along B lymphocyte development, cell survival 
is dependent from the production of Ig as membrane-
anchored receptors (mIg). That even plasma cell survival 
might somehow benefit from soluble Ig production is 
still debated [62-64]. While of major importance in 
physiology, the role played by BCR signaling and Ig 
production with regard to the maintenance or growth of 
malignant B cells is still incompletely appreciated. Except 
for very immature proliferations, most cases of B cell 
malignancies feature expression of Ig, either in the form 
of a membrane-anchored pre-BCR / BCR for lymphomas 
or as secreted Ig for plasma cell proliferations. In some 
types of malignancies, the biased use of canonical V (D) J 
rearrangements suggests the role of chronic antigen/BCR 
stimulation [65]. Some other lymphoma cases involve 
deregulated signaling by mutated components of the BCR 
cascade [11]. The class of the BCR or of the secreted 
monoclonal Ig often correlates with the phenotype 
Figure 3: Tumor cell variations according to size 
and c-myc expression: (A) Total cells from α1KI 
c-myc3’RR tumors or normal B cells from α1KI and 
wt control mice were stained with PC5-conjugated 
anti-B220, PE-conjugated anti-CD19 (Type Ia and Ib) 
or PE-conjugated anti-CD138+ (type II) and analyzed 
by cell cytometry. Shown is the forward scatter (FSC, directly 
evaluating cell size) of cells gated as [B220+/CD19+] for wt, 
α1KI, type Ia and Ib tumor B cells, or gated as [CD138+] for 
type II tumors. (B) Histograms showed the X-median of FSC 
gated as [B220+ /CD19+] cells for control and type Ia and Ib 
tumors, and gated on [CD138+] cells for type II tumors (n=4). 
(C) Quantitative PCR analysis of c-myc expression for tumors 
of type Ia (n=5), type Ib (n=5) and type II (n=2) compared to 
control splenocytes from α1KI (n=3). The relative expression 
is shown as bar graph. (NS, no significant; *, p <0.05; ***, p 
<0.001, unpaired t-test)
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of human B cell malignancies, IgM expression being 
associated with less differentiated tumors [15, 66]. This 
raises the question of whether specific BCR properties 
might influence the tumor phenotype and supply different 
cell growth and/or survival signals. Beside the role of Ig-
mediated tonic signals in cell survival, the ability of B 
cells to be activated and to differentiate relies on transient 
signals provided during BCR interaction with antigens. 
It is generally assumed that in immature B lymphocytes 
expressing IgM, early Ag contact leads to cell death or 
anergy while it promotes activation and differentiation 
of mature mIgM/mIgD-expressing B cells [67]. Also 
in class-switched mIgG+, mIgA+ or mIgE+ B cells and 
memory cells, BCR activation by antigen usually induces 
proliferation and differentiation into plasma cells. While 
all membrane Ig associate with the Ig-α / Ig-β complex 
to constitute the BCR, several studies have suggested that 
cells with a class-switched BCR hereby undergo some 
phenotypic changes. In particular, signaling from an 
IgG or IgA class BCR seems to induce more efficient B 
cell activation and short-term memory, while long-term 
accumulation as memory B cells might be a preferential 
feature of IgM expressing cells [8, 9, 61]. 
Among lymphomas, BL is characterized by the 
translocation of c-myc onto one of the Ig loci and the 
resulting c-myc deregulation then stands as the initial 
and driver hit [2]. It was shown in mice that the IgH 
locus 3’RR is instrumental for oncogenicity of c-myc 
translocations [68], which can also be artificially 
mimicked by associating a c-myc transgene with the 
IgH 3’RR [22]. The latter model induced two kinds 
of B cell neoplasias with different kinetics. Prevalent 
tumors overexpressed c-myc and arose at the mean age 
of 12 weeks with features resembling human BL: high 
proliferation, high level of apoptosis and a typical “starry 
sky” histological morphology, involving medium-sized 
mature B cells (B220+CD19+IgM+IgD+) with a basophilic 
cytoplasm. A second type of neoplasms arose at the 
mean age of 20 weeks, mostly involved liver and spleen, 
presented medium to large B220neg, CD138neg cells and 
were classified as anaplastic lymphomas [22, 23, 69].
In the present study, we backcrossed the c-myc3’RR 
transgene in the α1KI genetic background expressing a 
modified BCR of the IgA class. Such an IgA BCR was 
previously shown to yield high constitutive signaling in 
the absence of any BCR ligation. The present study shows 
that in double α1KI c-myc3’RR transgenic animals, the 
frequency of c-myc-driven tumors is decreased, their 
progression is lowered and the incurring lymphomas 
appear as more differentiated or even committed (in 10% 
of cases) into terminal BCR-, CD43+, CD138high plasma 
cell differentiation.
The slowed kinetics in the onset and progression 
of tumors is in agreement with the involvement of more 
differentiated cells. While all the tumors from the single 
transgenic mice were negative for both CD43 and CD138, 
most of double transgenic tumors have an activated 
phenotype with large CD43+ cells.
The c-myc oncogene has been described as 
a global regulator of various cell functions, and its 
overexpression usually results in tumorigenesis through a 
global deregulation of processes including increased cell 
proliferation, increased apoptosis, increased cell size, and 
marked changes in the total rate of protein synthesis [29, 
70, 71]. In that regard, c-myc increases transcription of 
ribosomal RNA genes, recruitment of rRNA processing 
factors, ribosomal subunit export and recruitment of 
translation initiation factors [72]. In addition, it was 
shown that the c-myc3’RR transgene yielded more diverse 
tumor phenotypes (including mantle cell lymphoma, BL 
and plasma cell lymphoma) upon association to other 
deregulated oncogenic processes in cdk4 [24, 73] or p53 
[23] mutant mice. 
In the present study, the IgA class BCR modifies 
c-myc–driven tumorigenesis by modulating genes 
involved in distinct biology function, then stimulating cell 
activation and differentiation while inhibiting cell growth. 
and further increasing the ribosome biogenesis and protein 
synthesis already targeted by c-myc. Interestingly, 3 of 
the genes up-regulated in IgA+ mouse lymphomas have 
already been underlined in human lymphomas as among 
the 6 genes suggested as sufficient to distinguish GC-type 
from ABC-type DLBCLs [74]. These genes are GADD34 
(up-regulated 12-fold), Myosin1 (up-regulated 5.9 fold) 
and fibronectin-1 (up-regulated 3.9 fold). Such genes up-
regulated both in GC-type vs ABC-type DLBCL and in 
IgA+ vs IgM+ mouse lymphomas, are reminiscent of the 
observation that GC-type DLBCLs mostly express class-
switched BCRs, while ABC-type DLBCLs mostly express 
IgM [14].
 Altogether, IgA tumors in α1KI c-myc3’RR double 
mutant animals have a modified phenotype by comparison 
to IgM tumors from single c-myc transgenic mice, 
showing that a class-switched BCR signal resulted in cell 
transformation with a more differentiated or activated 
lymphoid phenotype or even increased occurrence of 
plasma cell phenotypes, then reminiscent of human 
plasma cell proliferations that overwhelmingly produce 
class-switched Ig. This could also be pertinent to the 
observations made in patients, where IgM expressing 
malignancies are usually more aggressive than related 
class-switched proliferations, as noticed for the rare 
IgM myelomas, with lymphoplasmacytic rather than 
plasmacytic proliferations or as noticed for DLBCL, 
where the worse prognosis associates with the IgM-
expressing ABC-type.
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MATERIALS AND METHODS
Mice
All mice were in a C57Bl6 background previously 
shown to allow a nearly constant occurrence of c-myc-
driven lymphomas within the first 9 months of life [22]. 
The c-myc transgene includes the murine c-myc as a 
7-kb SmaI-KpnI genomic fragment including P1 and P2 
promoters, followed with the four IgH 3’RR enhancers: 
hs1,2 as a 0.6-kb StuI-EcoRV fragment flanked on both 
sides with hs3a and hs3b as two 2.1-kb EcoRI-HindIII 
fragments cloned with symmetric orientations, and hs4 
as a 1.38-kb PstI-HindIII fragment [25]. This c-myc 
expression cassette is flanked by β-globin insulators. The 
α1KI mutation corresponds to insertion of a 6 kb IgH Cα1 
human genomic fragment (from upstream of CH1α to a 
BamHI site downstream of the membrane-form transcript 
polyadenylation signal) in replacement of the mouse IgH 
Sµ region [6]. The project was approved by our local ethics 
committee review board. Mice were followed daily for 
clinical examination and macroscopic tumor development. 
Animal exhibiting important tumors or presenting severe 
signs of anemia or illness were sacrificed. 
Southern blot analysis
Genomic DNA was extracted from mice tails. Ten 
µg of DNA were digested with EcoRI, loaded on 0.7% 
agarose gels, transferred on nylon sheets (Amersham, 
Buckinghamshire, UK), hybridized with a 32P-labeled 
hs4 probe (a 1.3 kb PstI fragment) and autoradiographed 
to ensure the presence of the c-myc3’RR transgene as 
previously reported [22] . 
Clonality of tumors was also assayed by southern 
blots of EcoRI digested tumor DNAs, with an IgH probe 
located around the JH4 segment (a 0.5kb SacI-NaeI 
fragment).
In vitro stimulation assays. 
Splenic B cells from α1KI c-myc3’RR and α1KI 
homozygous control mice were stimulated for 3 days with 
20 µg/mL of LPS from Salmonella typhimurium (Sigma, 
St-Louis, MO) or with 5 μg/mL anti-CD40 (R&D systems, 
Lille, France) plus 40 ng/mL murine  IL4 (PeproTech) 
in RPMI supplemented with 10% heat-inactivated fetal 
calf serum. The number of viable proliferating cells was 
assessed using MTS solution [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium], and a colorimetric assay (Promega) 
following the manufacturer’s recommendations. 
mRNA expression
Total RNA was extracted from fresh tissues and 
cell suspensions using tri-reagent (Ambion Austin, TX). 
RNA was reverse-transcribed into cDNA by addition of 
reverse transcriptase to 2 µg total RNA in a final volume 
of 20 µl. Real-time PCR was performed in duplicate by 
using TaqMan assay reagents and analyzed on an ABI 
Prism 7000 system (Applied Biosystems Foster City, CA). 
Transcripts analyzed were c-myc (Mm00487803-m1) and 
18S RNA (Hs99999901-s1) used for gene expression level 
normalization (Applied Biosystems). 
Microarray preparations
RNA was extracted from hyperplasic lymph nodes 
(LNs). Experiments were done in quadruplicate and 0.2µg 
of RNA was used for each microarray analysis. cDNA 
labeling and dual color microarray hybridization were 
done in the Nice Sophia-Antipolis Microarray Facility 
(Nice Sophia Antipolis, France). 
Gene Data Expression Analyses
Cluster analysis.  GenBank accession number 
- GSE 32229. Log 2 signals were extracted after 
interslide quantile normalization and performed with R 
(Bioconductor). Probe sets showing minimal variation 
across all samples were filtered out, only retaining those 
3217 with a coefficient of variation over 0.1, and using 
them to cluster the samples through the hierarchical 
agglomerative algorithm. Average linkage and Euclidian 
distance were used as linkage and similarity methods, 
respectively. Supervised classification was carried out 
using Cluster and TreeView software.
Detection of differentially expressed 
genes. Statistical analyses used the R and Bioconductor 
software. To identify over- or under-expressed genes, 
we used the empirical Bayesian method for differential 
expression calculation [26] implemented in the Linear 
Models for Microarray Analysis (LIMMA) package. For 
each pairwise comparison, p-values were adjusted after 
multiple testing corrections using the Benjamini and 
Hochberg method [27]. Probes with a corrected p value 
below 0.05 were considered as differentially expressed. 
Futhermore, gene lists of enriched pathways were 
generated using Ingenuity Pathway Analysis.
Flow cytometry analysis
Cell suspensions from spleen, liver and LNs were 
stained with various antibodies (Southern Biotechnologies 
or eBiosciences): SpectralRed (PC5)-conjugated 
anti-B220, phycoerythrin-labeled (PE) anti-CD19, anti-
Oncotarget9www.impactjournals.com/oncotarget
CD138, FITC-conjugated anti-human IgA and PE anti-
mouse CD43. Cells were analyzed on a Coulter XL 
apparatus (Beckman Coulter, Fullerton, CA).
Blood sampling
Blood samples were collected from transgenic and 
wild-type (wt) mice with heparinised needles. Blood 
smears allowed differential counting of blood cells after 
staining by the May-Grünwald-Giemsa method.
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